PXD071884-1

PXD071884 is an original dataset announced via ProteomeXchange.

Title	A Minimally-invasive Extracellular Vesicle-based Approach for Monitoring Measurable Residual Disease in Acute Myeloid Leukemia
Description	Measurable residual disease (MRD) in acute myeloid leukemia (AML) is monitored through detection of leukemia associated phenotypic protein markers (LAPMs) in bone marrow aspirates, hindering disease real-time monitoring. We explored peripheral blood (PB) extracellular vesicles (EVs)-based methods for MRD monitoring. To confirm that LAPMs are present in AML-derived EVs, EVs were isolated from OCI-AML3 cells by dif-ferential centrifugation, and characterized according to their size (nanoparticle tracking analysis), morphology (transmission electron microscopy) and protein cargo (proteomic analysis and Western blot). CD14 and CD33 were detected in OCI-AML3 cells and their released EVs. To select a method to isolate EVs from the PB of AML patients, three tech-niques were tested: size exclusion chromatography followed by ultrafiltration (SEC-UF), Total Exosome Isolation Kit (Invitrogen) and Exo-spin™ Exosome Purification Kit (Cell Guidance Systems). SEC-UF allowed EVs isolation with higher purity and less aggregates than the other techniques. LAPMs were detected in those EVs but their presence depended on the isolation method. Finally, EVs from seven AML patients’ plasma were isolated by SEC-UF. LAPMs were identified in paired samples at diagnosis and remission, with dif-ferential expression throughout disease evolution. This work highlights the possibility of real-time MRD monitoring through LAPMs’ analysis in AML patient’s circulating EVs.
HostingRepository	PRIDE
AnnounceDate	2026-06-29
AnnouncementXML	Submission_2026-06-28_16:31:23.526.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Hugo Osorio
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606;
ModificationList	iodoacetamide derivatized residue
Instrument	Q Exactive

Revision	Datetime	Status	ChangeLog Entry
0	2025-12-11 13:01:33	ID requested
⏵ 1	2026-06-28 16:31:24	announced

Branco H, Carreira J, Soure I, Xavier CPR, Ros, á, rio A, Amorim M, Os, ó, rio H, Guimar, ã, es JE, Sarmento-Ribeiro AB, Sobrinho-Sim, õ, es MA, Caires HR, Vasconcelos MH, A Minimally Invasive, Extracellular Vesicle-Based Approach for Monitoring Measurable Residual Disease in Acute Myeloid Leukemia: A Proof-of-Concept Study. Cells, 15(12):(2026) [pubmed]

10.3390/cells15121068;

submitter keyword: Acute Myeloid Leukemia

Measurable Residual Disease

Liquid Biopsies

Extracellular Vesicles

Maria Helena Vasconcelos
contact affiliation	1 - i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal; 2 - Cancer Drug Resistance Group, IPATIMUP – Institute of Molecular Pathology and Immunology, University of Porto, Rua Júlio Amaral de Carvalho 45, 4200-135 Porto, Portugal; 3 - Department of Biological Sciences, FFUP – Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal
contact email	hvasconcelos@ipatimup.pt
lab head
Hugo Osorio
contact affiliation	i3S - Institute for Research and Innovation in Health, University of Porto
contact email	hosorio@i3s.up.pt
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/06/PXD071884

PRIDE project URI

• PRIDE
  1. PXD071884
     1. Label: PRIDE project
     2. Name: A Minimally-invasive Extracellular Vesicle-based Approach for Monitoring Measurable Residual Disease in Acute Myeloid Leukemia